Profil
Ann C.
Neale held several positions in the pharmaceutical industry, including Senior Director of Operations & Development Planning at ARYx Therapeutics, Principal at Applied Immune Sciences and Syntex Corp, Vice President of Clinical Operations at Synosia Therapeutics AG, and Head of Clinical Research at Angiochem, Inc. She also served as Vice President of Clinical Operations at Saegis Pharmaceuticals, Inc. from 2004 to 2009.
Neale received her undergraduate degree from the University of Minnesota in 1985.
Anciens postes connus de Ann C. Neale
| Sociétés | Poste | Fin |
|---|---|---|
Saegis Pharmaceuticals, Inc.
 Saegis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA. | Directeur Technique/Scientifique/R&D | 17/02/2009 |
Synosia Therapeutics, Inc.
 Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Directeur Technique/Scientifique/R&D | - |
| Syntex Corp. | Corporate Officer/Principal | - |
Applied Immune Sciences, Inc.
 Applied Immune Sciences, Inc. Medical SpecialtiesHealth Technology Part of Sanofi, Applied Immune Sciences, Inc. is a surgical and medical instruments company. The company is based in Menlo Park, CA. The company was founded by Thomas B. Okarma. Applied Immune Sciences was acquired by Rhone-Poulenc Rorer, Inc. on November 28, 1995 for $84.40 million. | Corporate Officer/Principal | - |
Formation de Ann C. Neale
| University of Minnesota | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARYX THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Applied Immune Sciences, Inc.
Applied Immune Sciences, Inc. Medical SpecialtiesHealth Technology Part of Sanofi, Applied Immune Sciences, Inc. is a surgical and medical instruments company. The company is based in Menlo Park, CA. The company was founded by Thomas B. Okarma. Applied Immune Sciences was acquired by Rhone-Poulenc Rorer, Inc. on November 28, 1995 for $84.40 million. | Health Technology |
| Syntex Corp. | Health Technology |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Mimetix, Inc.
 Mimetix, Inc. Pharmaceuticals: MajorHealth Technology Part of Symbollon Pharmaceuticals, Inc., Mimetix, Inc. develops pharmaceutical products with a focus on iodine drug therapy. Mimetix was acquired by Symbollon Pharmaceuticals, Inc. on July 01, 2004 for $0.80 million. | Health Technology |
Saegis Pharmaceuticals, Inc.
Saegis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA. | Health Technology |
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Synosia Therapeutics, Inc.
Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Health Technology |
